Capricor Therapeutics Inc

Insider buying in Capricor shows strategic confidence: Litvack Frank’s low‑price share purchase signals long‑term commitment amid strong clinical results and a $279 M cash runway.

Capricor Therapeutics insider sale: Director Sabar Karimah Es sells 7,529 shares at $32.11 per share, a Rule 144 transaction that’s market‑neutral and part of a disciplined equity‑compensation plan – a routine liquidity move amid bullish biotech mom…

Capricor insiders, led by Sabar Karimah Es, buy low at $4.86 and sell near $30–$31, showing confidence in future upside amid a negative P/E and a Duchenne pipeline.

Capricor insiders exercise 50,000 zero‑cost options—signaling confidence in its DMD pipeline and potential share price rally.

Capricor’s insider option buys signal confidence in its Duchenne therapy pipeline, but investors should weigh clinical risks and market volatility.